InvestorsHub Logo
Followers 2
Posts 2022
Boards Moderated 0
Alias Born 05/11/2017

Re: gajj post# 99135

Thursday, 05/23/2019 11:48:44 AM

Thursday, May 23, 2019 11:48:44 AM

Post# of 108191
You should know very well that Ph3 and EU submission were two separate things. Phase 3 trial to see how AXAL works as the adjuvant therapy, while Phase 2 was completed as a late stage cancer drug. EU submission was based on Ph2 data plus some other older data. The management decided the data was sufficient to get a conditional approval in EU. Wrong. They should have known that, and they had no clue. Reckless and incompetent. Wasted a lot of time, resources and cash on nothing burger.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News